Side-by-side comparison of AI visibility scores, market position, and capabilities
Seattle AI drug discovery targeting transcription factors with MARMOT platform measuring 10,000 regulomes monthly; YC W21 $11.2M with FDA/EMA Phase I approval for MSD-001 cancer program.
Talus Bioscience is a Seattle-based AI-powered drug discovery company targeting transcription factors — the class of proteins historically considered "undruggable" that regulate gene expression and drive many cancers — using its proprietary MARMOT platform (MAssive Regulome Mapping Of Transcriptomes) to measure the binding activity of small molecules across 10,000+ regulomes monthly using live, unmodified human cells. Founded and backed by Y Combinator (W21) with $11.2 million in Seed+ funding raised in August 2024, Talus received FDA and EMA approval for Phase I human trials of its lead program MSD-001 in 2024 — advancing toward first-in-human studies for a transcription factor-targeted cancer therapy.
Bucket Robotics builds modular autonomous mobile robots for warehouse and industrial environments, designed for rapid deployment without requiring fixed infrastructure or facility modifications.
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse automation systems that require significant facility modifications, fixed conveyors, and multi-month installation projects, Bucket Robotics' AMRs navigate dynamically using onboard sensors and AI, allowing deployment in existing facilities without permanent infrastructure changes.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.